| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 51.22 | 1033.2% | 17.4% |
| Total Income | 51.22 | 1033.2% | 17.4% |
| Expenditure | 88.29 | 7.2% | 15.0% |
| PBT | -21.92 | 83.0% | 29.5% |
| Net Profit | -21.73 | 83.1% | 29.5% |
| OPM | -72.37% | 3.70pp | |
| NPM | -42.42% | 28.27pp | |
| EPS | -0.29 | 83.0% | 29.3% |
Xencor Announces $105 Million Settlement with Alexion and Extends Cash Runway to 2028
30 Jul 2026 · 30 Jul, 1:42 am
Summary
Xencor, Inc. announced a settlement agreement with Alexion Pharma International Operations Limited to resolve a commercial dispute concerning U.S. royalties on Ultomiris®. Under the agreement, Xencor will receive $105 million in two payments and Alexion will cease U.S. royalty obligations. The company anticipates this resolution will provide immediate capital and extend its operating runway through 2028, allowing continued funding for research and development programs.
Key Highlights
- 1
Xencor will receive $105 million from Alexion to resolve a commercial dispute related to U.S. royalties on Ultomiris®.
- 2
The settlement includes two equal payments of $52.5 million, with the first anticipated in August 2026.
- 3
Alexion will have no further obligation to pay royalties on U.S. sales of Ultomiris following this agreement.
- 4
Xencor expects to continue receiving royalties on ex-U.S. sales of Ultomiris under existing terms.
- 5
The company expects to have cash to fund research and development programs and operations through 2028.
Management Comments
Bassil Dahiyat
We are pleased to have reached a resolution that provides immediate capital and reflects the value of the U.S. royalty stream that we had previously expected through 2028. We have returned our operating runway estimate to extend through 2028.
Informational and educational content only. Not investment advice.